Plain-English translation of NCT05359263 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing dapagliflozin, a medication that may help protect the heart in people with chronic kidney disease. Researchers want to see whether this treatment can improve how the heart is structured and how well it pumps blood. The study will last 6 months and will carefully measure changes in heart health using ultrasound images and blood tests.
People with chronic kidney disease often develop heart problems, and current treatments don't always prevent this. This study explores whether this medication might offer additional heart protection beyond what patients are already receiving.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the medication or a placebo (dummy pill) once daily for 6 months. At the start and end of the study, you'll have heart ultrasound scans, blood and urine tests, and assessments of your quality of life and mood. You'll visit the clinic at baseline and after 6 months of treatment to complete these measurements.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
Denmark
Testing effectiveness
Sponsor
Tor Biering-Sørensen
Enrollment target
~222 participants
Started
June 2022
Primary completion
February 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Katja Vu Bartholdy, MD
Research Director
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.